C A Zarate

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study
    C A Zarate
    Bipolar and Psychotic Disorders Research Program, McLean Hospital, Belmont, MA, USA
    J Clin Psychiatry 61:33-8. 2000
  2. ncbi request reprint Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry
    Allison C Nugent
    Section on Neuroimaging in Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 1 Center Drive, MSC 0135, Bethesda, MD 20892 0135, USA
    Neuroimage 30:485-97. 2006
  3. ncbi request reprint Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients
    Carlos A Zarate
    Consolidated Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass, USA
    Am J Psychiatry 161:169-71. 2004
  4. ncbi request reprint Cycling into depression from a first episode of mania: a case-comparison study
    C A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892, USA
    Am J Psychiatry 158:1524-6. 2001
  5. ncbi request reprint An open-label trial of riluzole in patients with treatment-resistant major depression
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics and the Pathophysiology Branch, Mood and Anxiety Disorders Program, NIMH, Department of Health and Human Services, NIH, Bethesda, MD 20892, USA
    Am J Psychiatry 161:171-4. 2004
  6. ncbi request reprint Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1003:273-91. 2003
  7. ncbi request reprint Combination treatment in bipolar disorder: a review of controlled trials
    Carlos A Zarate
    The Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892, USA
    Bipolar Disord 5:217-25. 2003
  8. ncbi request reprint Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
    J A Quiroz
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:756-76. 2004
  9. ncbi request reprint Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
    T D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:734-55. 2004
  10. ncbi request reprint Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics
    H K Manji
    Laboratory of Molecular Pathophysiology, NIMH, Bethesda, MD 20892 4405, USA
    Mol Psychiatry 7:S1-7. 2002

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study
    C A Zarate
    Bipolar and Psychotic Disorders Research Program, McLean Hospital, Belmont, MA, USA
    J Clin Psychiatry 61:33-8. 2000
    ..To determine the use of antipsychotics during and following inpatient treatment of patients with a first-episode of mania...
  2. ncbi request reprint Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry
    Allison C Nugent
    Section on Neuroimaging in Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 1 Center Drive, MSC 0135, Bethesda, MD 20892 0135, USA
    Neuroimage 30:485-97. 2006
    ....
  3. ncbi request reprint Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients
    Carlos A Zarate
    Consolidated Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass, USA
    Am J Psychiatry 161:169-71. 2004
    ..The goal of this study was to determine the benefits of the continued use of a typical antipsychotic agent following remission from an acute manic episode...
  4. ncbi request reprint Cycling into depression from a first episode of mania: a case-comparison study
    C A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892, USA
    Am J Psychiatry 158:1524-6. 2001
    ..The characteristics of patients who cycle from mania to major depression and the frequencies of these cycles remain poorly understood...
  5. ncbi request reprint An open-label trial of riluzole in patients with treatment-resistant major depression
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics and the Pathophysiology Branch, Mood and Anxiety Disorders Program, NIMH, Department of Health and Human Services, NIH, Bethesda, MD 20892, USA
    Am J Psychiatry 161:171-4. 2004
    ..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression...
  6. ncbi request reprint Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1003:273-91. 2003
    ....
  7. ncbi request reprint Combination treatment in bipolar disorder: a review of controlled trials
    Carlos A Zarate
    The Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892, USA
    Bipolar Disord 5:217-25. 2003
    ..This article reviews the available published data from controlled, blinded studies regarding combination treatments in the different treatment phases of bipolar disorder...
  8. ncbi request reprint Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
    J A Quiroz
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:756-76. 2004
    ..While the task of developing novel medications for bipolar disorder is truly daunting, these and similar approaches will ultimately lead to better medications for the millions who suffer from this devastating illness...
  9. ncbi request reprint Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
    T D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:734-55. 2004
    ....
  10. ncbi request reprint Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics
    H K Manji
    Laboratory of Molecular Pathophysiology, NIMH, Bethesda, MD 20892 4405, USA
    Mol Psychiatry 7:S1-7. 2002
  11. pmc Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Nat Rev Drug Discov 7:426-37. 2008
    ..We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders...
  12. ncbi request reprint A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 63:856-64. 2006
    ..Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders...
  13. ncbi request reprint The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 32:793-802. 2007
    ....
  14. ncbi request reprint Regional cerebral glucose metabolic abnormalities in bipolar II depression
    Linda Mah
    Section on Neuroimaging in Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    Biol Psychiatry 61:765-75. 2007
    ..This study investigated whether cerebral metabolic abnormalities previously reported in unmedicated BD subjects are evident in depressed bipolar disorder type II (BD II) subjects receiving lithium or divalproex...
  15. ncbi request reprint Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials
    Jaskaran B Singh
    Mood and Anxiety Disorders Research Program, National Institute of Mental Health, 10 Center Drive, Bethesda, MD 20892, USA
    Bipolar Disord 8:696-709. 2006
    ..The aim of this review was to summarize the literature on controlled pharmacological trials that have been conducted in psychiatric conditions that commonly co-occur in bipolar disorder...
  16. pmc Riluzole in psychiatry: a systematic review of the literature
    Carlos A Zarate
    Mark O Hatfield CRC, Bethesda, Maryland 20892, USA
    Expert Opin Drug Metab Toxicol 4:1223-34. 2008
    ..Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral sclerosis (ALS) is one such agent...
  17. ncbi request reprint Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial
    Roy H Perlis
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:1747-53. 2006
    ..To compare olanzapine and risperidone in the treatment of nonpsychotic acute manic or mixed episodes...
  18. ncbi request reprint Performance on a virtual reality spatial memory navigation task in depressed patients
    Neda F Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, NIMH, Mark O Hatfield Clinical Research Center, 10 Center Dr, Bethesda, MD 20892, USA
    Am J Psychiatry 164:516-9. 2007
    ..Findings on spatial memory in depression have been inconsistent. A navigation task based on virtual reality may provide a more sensitive and consistent measure of the hippocampal-related spatial memory deficits associated with depression...
  19. ncbi request reprint Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
    Sungho Maeng
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Biol Psychiatry 63:349-52. 2008
    ..Understanding the mechanisms underlying the intriguing effects of N-methyl d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action...
  20. ncbi request reprint Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Bipolar Disord 9:561-70. 2007
    ..In this study, we investigated whether antimanic effects can be achieved with a protein kinase C inhibitor in subjects with mania...
  21. pmc A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania
    Rodrigo Machado-Vieira
    Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, RS, Brazil
    J Clin Psychiatry 69:1237-45. 2008
    ..This study aimed to evaluate the efficacy and tolerability of the purinergic agents allopurinol and dipyridamole combined with lithium in bipolar mania...
  22. pmc Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder
    Rodrigo Machado-Vieira
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, MD 20892 1282, USA
    J Clin Psychiatry 69:946-58. 2008
    ..This article reviews the published data related to different aspects of rapid improvement of depressive symptoms...
  23. ncbi request reprint Neurobiology of bipolar disorder
    Andrew R Newberg
    National Institute of Mental Health, 10 Center Drive, MSC 1282, Building 10 CRC, Room 7 5545, Bethesda, MD 20892 1282, USA
    Expert Rev Neurother 8:93-110. 2008
    ....
  24. ncbi request reprint The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects
    Sungho Maeng
    Curr Psychiatry Rep 9:467-74. 2007
    ....
  25. pmc The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Exp Neurol 211:7-10. 2008
  26. ncbi request reprint Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 59:1006-20. 2006
    ....
  27. ncbi request reprint A double-blind, placebo-controlled study of memantine in the treatment of major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA
    Am J Psychiatry 163:153-5. 2006
    ..This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans...
  28. ncbi request reprint Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder
    Kristine Erickson
    Mood and Anxiety Disorders Program, National Institute of Mental Health, MD 20814 9692, USA
    Am J Psychiatry 162:2171-3. 2005
    ..This study investigated performance of unmedicated depressed patients on the Affective Go/No-Go Task...
  29. ncbi request reprint Olanzapine versus divalproex in the treatment of acute mania
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 159:1011-7. 2002
    ..The effects of olanzapine and divalproex for the treatment of mania were compared in a large randomized clinical trial...
  30. ncbi request reprint The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence
    Mauricio Tohen
    Lilly Research Laboratories, Brougher Building, 525 South Meridian, Indianapolis, IN 46225, USA
    Am J Psychiatry 160:2099-107. 2003
    ..Since improved prediction of illness course early in bipolar disorder is required to guide treatment planning, the authors evaluated recovery, first recurrence, and new illness onset following first hospitalization for mania...
  31. ncbi request reprint Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression
    Husseini K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892 4405, USA
    Biol Psychiatry 53:707-42. 2003
    ..The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders...
  32. ncbi request reprint Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
    ..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex...
  33. ncbi request reprint Olanzapine versus placebo in acute mania: treatment responses in subgroups
    Ross J Baldessarini
    International Consortium for Bipolar Disorder Research, Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
    J Clin Psychopharmacol 23:370-6. 2003
    ..5-1.7, all P < 0.01). These well-powered comparisons of subgroups of interest indicate broad efficacy of olanzapine in the treatment of acute mania...
  34. ncbi request reprint Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine
    Jaskaran Singh
    Psychopharmacology (Berl) 173:227-8. 2004
  35. ncbi request reprint Glycogen synthase kinase-3: a target for novel bipolar disorder treatments
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA
    J Clin Psychiatry 65:10-21. 2004
    ..We conclude with a discussion of the GSK-3 inhibitors furthest in development and the clinical trials that may emerge...
  36. ncbi request reprint A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression
    Susan L McElroy
    Psychopharmacology Research Program, University of Cincinnati College of Medicine, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 65:204-10. 2004
    ..Lamotrigine has demonstrated efficacy for the acute treatment of depression in bipolar I patients in a placebo-controlled, monotherapy study. We describe the results of a 52-week, open-label continuation of that trial...
  37. ncbi request reprint Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 184:337-45. 2004
    ..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone...
  38. pmc Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets
    Paul J Carlson
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    NeuroRx 3:22-41. 2006
    ....
  39. ncbi request reprint An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 57:430-2. 2005
    ..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar depression...
  40. ncbi request reprint Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institute of Health, Department of Human and Health Services, Bethesda, Maryland, USA
    Biol Psychiatry 56:54-60. 2004
    ..The current study was undertaken as a proof of the concept that dopamine agonists will be effective in patients with bipolar II depression...
  41. ncbi request reprint Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy
    Mauricio Tohen
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 59:62-9. 2002
    ....
  42. ncbi request reprint Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?
    Jennifer L Payne
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892 1283, USA
    Biol Psychiatry 52:921-6. 2002
    ....
  43. ncbi request reprint Overweight and obesity in bipolar disorders
    Po W Wang
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Room 2117, CA 94305 5723, USA
    J Psychiatr Res 40:762-4. 2006
  44. ncbi request reprint Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profiling
    Rulun Zhou
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892 3711, USA
    Int J Neuropsychopharmacol 9:263-6. 2006
  45. pmc Increased rate of non-right-handedness in patients with bipolar disorder
    Cecylia Nowakowska
    J Clin Psychiatry 69:866-7. 2008